Abstracts tagged "juvenile arthritis and pediatric rheumatology"

Abstract Number: 381 • 2017 ACR/ARHP Annual Meeting
Down’s Arthritis (DA) – Clinical and Radiological Features of Arthritis in Children with Trisomy 21
Charlene Foley, Emma Jane Mac Dermott and Orla Killeen, National Centre for Paediatric Rheumatology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
Background/Purpose: Down's Arthritis (DA) was first reported in the literature in 1984. Crude estimates suggest higher incidence and prevalence rates of DA compared with Juvenile…
Abstract Number: 317 • 2014 ACR/ARHP Annual Meeting
Myeloid Related Proteins 8 and 14 (MRP 8/14) – Potential Biomarkers of Disease Activity of Arthritis in Children with Trisomy 21
Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland
Background/Purpose JIA is an umbrella term used to describe a heterogeneous group of diseases.To date no specific markers exist in clinical practice to predict disease…
Abstract Number: 861 • 2012 ACR/ARHP Annual Meeting
A Family Based Pedometer Walking Program in an Adolescent Population with Juvenile Idiopathic Arthritis
Sara M. Stern¹, Jill R. Blitz², Amber Richards² and Katherine AB Marzan³, ¹Pediatric Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Rehab Services, Children's Hospital Los Angeles, Los Angeles, CA, ³Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Walking programs are effective in adult arthritis but have not been studied in adolescents with arthritis. The study’s objective was to evaluate the impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].